Matthew Greenhawt
Overview
Explore the profile of Matthew Greenhawt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
278
Citations
3404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanders J, Conway A, Kartha N, Kumar B, Oppenheimer J, Verdi M, et al.
Ann Allergy Asthma Immunol
. 2025 Mar;
PMID: 40088222
Background: Food protein-induced enterocolitis syndrome (FPIES) affects approximately 0.5% of US children. Oral food challenges (OFCs) are frequently conducted to assess FPIES resolution in an observed setting, given the risk...
2.
Greenhawt M, Albright D, Anvari S, Arends N, Arkwright P, Begin P, et al.
J Allergy Clin Immunol Pract
. 2025 Feb;
PMID: 39956162
Background: The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment...
3.
Anagnostou A, Greenhawt M, Lieberman J, Ciaccio C, Sindher S, Creasy B, et al.
J Allergy Clin Immunol Glob
. 2025 Jan;
4(1):100379.
PMID: 39844911
Background: Management of patients with food allergies is complex, especially in cases of patients with multiple and potentially severe food allergies. Although international guidelines exist for food allergy management, the...
4.
Yin Y, Shoshan M, Shaker M, Greenhawt M, Johnson K
Allergy Asthma Clin Immunol
. 2025 Jan;
21(1):5.
PMID: 39844311
Background: Until recently, immediate emergency department (ED) transfer after food-related anaphylactic reactions was recommended regardless of symptom resolution following use of an epinephrine autoinjector (EAI). We evaluated the cost-effectiveness of...
5.
Kraus C, Wargacki S, Golden D, Lieberman J, Greenhawt M, Camargo Jr C
Ann Allergy Asthma Immunol
. 2025 Jan;
PMID: 39826899
Background: Epinephrine is the first-line treatment for anaphylaxis and is administered through intramuscular or subcutaneous injection. AQST-109, a sublingual film containing the prodrug epinephrine, was developed as an alternative delivery...
6.
Adams K, Greenhawt M, Bingemann T, Tracy J, Brooks J, Otto H, et al.
J Allergy Clin Immunol Pract
. 2025 Jan;
13(3):501-510.
PMID: 39755273
Background: The evaluation and management of insect sting allergy is a complex core competency taught in Allergy and Immunology fellowship programs. It is unclear whether current training on insect allergy...
7.
Dantzer J, Shaker M, Greenhawt M
J Allergy Clin Immunol Pract
. 2024 Dec;
PMID: 39709051
The current US Food and Drug Administration (FDA) paradigm may not fully capture important patient-centered outcomes or measure a primary outcome that is truly meaningful to patients. Patient-reported outcome measures...
8.
Lloyd M, Morton J, Peters R, Loke P, Ashley S, Shaker M, et al.
J Allergy Clin Immunol Pract
. 2024 Dec;
13(3):619-629.
PMID: 39675524
Background: Egg oral immunotherapy (OIT) can induce desensitization or remission of egg allergy in children. Objective: To determine the cost-effectiveness of OIT for raw egg allergy in school-age children compared...
9.
Shaker M, Anagnostou A, Greenhawt M, Prince B, Sokol K
Ann Allergy Asthma Immunol
. 2024 Dec;
PMID: 39643040
No abstract available.
10.
Shaker M, Oppenheimer J, Rider N, Golden D, Anagnostou A, Greenhawt M
Ann Allergy Asthma Immunol
. 2024 Dec;
PMID: 39637974
Background: Noninjectable epinephrine to treat allergic reactions addresses an unmet need. Intranasal epinephrine is approved and a sublingual form is under development. Inhaled epinephrine is poorly studied for anaphylaxis. These...